The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Celgene; Halozyme; Incyte; Ipsen; Klus Pharma; Newlink Genetics; QED Therapeutics
Research Funding - Agios (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); FibroGen (Inst); Halozyme (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; FibroGen; FibroGen
 
Amy E. Chang
No Relationships to Disclose
 
Oxana V. Crysler
Research Funding - ACCRU (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
David Bing Zhen
No Relationships to Disclose
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Cancer Commons; Ipsen; Legend Biotech
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmuneSensor Therapeutics (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst)
 
Timothy S. Pardee
Consulting or Advisory Role - Abbvie; Genentech; Rafael Pharmaceuticals
Speakers' Bureau - Amgen; Celgene; Novartis; Pharmacyclics
Research Funding - Karyopharm Therapeutics; Rafael Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Named on a provisional patent on the use of KPC34 for the treatment of acute leukemias.
Travel, Accommodations, Expenses - Pharmacyclics; Rafael Pharmaceuticals
 
Sanjeev Luther
Employment - Rafael Pharmaceuticals
Leadership - Rafael Pharmaceuticals
Stock and Other Ownership Interests - Rafael Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Pending
Travel, Accommodations, Expenses - Rafael Pharmaceuticals
 
Kent A. Griffith
No Relationships to Disclose
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; Merck; Newlink Genetics/Pharmatech; Oncomed; Seagen